Maha Katabi, PhD, CFA, is a General Partner at Sofinnova Investments. See sector focus and contact routes.
Maha Katabi, PhD, CFA, is a General Partner at Sofinnova Investments, where she joined in 2019 after serving as a Partner at Sectoral Asset Management and leading private investment teams. She manages investments across the life sciences sector with over two decades of experience in both public and private biotech companies through varying market cycles. Her investment focus spans clinical-stage biopharmaceuticals, including biotechnology, pharmaceuticals, and digital health, typically engaging in Series A through Series E rounds. Katabi has co-invested with Sofinnova in notable companies such as Apellis Pharmaceuticals, Ascendis Pharma, and Trius Therapeutics, and currently serves on the boards of ARTBIO, Marea Therapeutics, Quanta Therapeutics, and Vera Therapeutics. While specific check sizes and lead/follow behavior are not publicly detailed, her track record includes multiple board memberships and successful acquisitions like RayzeBio (acquired by BMS) and Aiolos (acquired by GSK). Recognized by Fierce Pharma as one of 2023’s Fiercest Women in Life Sciences, she also advises amplifyHERscience, a Yale Ventures initiative, reflecting a commitment to
StartupFundraising tracks this investor record from SEC filings and announced rounds, updating focus, location and portfolio history as new data lands. Use it to gauge fit before an outreach, then widen the search to investors in Montréal.
Investors like Maha Katabi · Full investor directory · Investor access · Company funding database